Research Blog
Expert analysis, breaking news, and informed commentary on retatrutide research, clinical trial updates, conference presentations, and regulatory milestones.
FDA Says Retatrutide Is a Drug, Not a Biologic: What It Means
On October 2, 2026 the FDA ruled retatrutide is a drug, so it must be filed as an NDA, not a BLA. The 40-amino-acid rule, the court case and what changes.
Black-Market Retatrutide: Reported Deaths and Real Dangers
Two deaths linked to black-market 'Reta' were reported to the FDA in 2026. What the reports say, what lab tests found, and why the cause is unproven.
Retatrutide's Published Trials, Explained in Plain Language
What the NEJM and Lancet papers on retatrutide report: TRIUMPH-1, TRIUMPH-2, sleep apnea, TRANSCEND-T2D-1 and Phase 2, and why the headline numbers differ.
Retatrutide Side Effects Outside Trials: What Users Report
A JAMA Network Open study of 7,823 people taking unapproved retatrutide: appetite, fatigue, nausea and heart-rate complaints, compared with the trial data.
Retatrutide Black Market, Late 2026: Lawsuits, FDA Letters, Counterfeits
Lilly sued six sellers, the FDA named 'GLP-3 Reta' in warning letters, grey-market users lost half the trial weight, and a counterfeit vial was 8x semaglutide.
Retatrutide Expanded Access: Who Qualifies and How Doctors Apply
Lilly's pre-approval program (NCT07629401) is for BMI 35+ despite approved drugs, two serious complications and no trial nearby. Only doctors can apply.
TRIUMPH-2 and TRIUMPH-3 Results: Retatrutide in Diabetes and Heart Disease
Eli Lilly's July 23, 2026 readouts: -20.8% weight loss with type 2 diabetes, -22.6% with cardiovascular disease, dysesthesia 6-7%, and a filing planned for Q1 2027.
What Is MASH? Retatrutide's Liver-Disease Program Explained
How retatrutide targets MASH liver disease: the glucagon-driven liver-fat effect, plus what the SYNERGY-OUTCOMES and MACELD Phase 3 trials aim to prove.
How Was Retatrutide Discovered? The Triple-Agonist Story
Retatrutide was built by adding glucagon action to the GIP/GLP-1 backbone behind tirzepatide. Inside the discovery science of the first triple agonist.
When Was Retatrutide Created? Timeline 2016 to 2026
Retatrutide entered human trials in 2019, about 7 years ago. A year-by-year timeline from its 2016 design to 2026 Phase 3 data — still investigational.
Retatrutide at ADA 2026: TRIUMPH-1 and TRANSCEND-T2D-1 Deliver — and Get Published in The Lancet
What was presented at ADA 2026 on June 6: full TRIUMPH-1 obesity data and TRANSCEND-T2D-1 diabetes results, published the same day in The Lancet.
TRIUMPH-1 Phase 3 Results: Retatrutide Delivers 28.3% Weight Loss in 2,339-Patient Obesity Trial
TRIUMPH-1, retatrutide's main Phase 3 obesity trial (2,339 adults): 28.3% average weight loss at 12 mg over 80 weeks. Results, side effects, what's next.
Next-Gen Obesity Drugs Compared: The 2026 Pipeline
Comparing retatrutide, orforglipron, amycretin, MariTide, survodutide, and VK2735 — mechanisms, efficacy data, and timelines as of April 2026.
Diet and Nutrition on Retatrutide: A Practical Guide
What to eat on retatrutide, how much protein you need, hydration strategies, and micronutrients to watch — based on clinical trial data.
Retatrutide Drug Interactions: What Clinicians Should Know
Analysis of potential retatrutide drug interactions based on GLP-1 class effects, including oral contraceptives, metformin, insulin, and anticoagulants.
Retatrutide and Hair Loss: What the Evidence Actually Says
Is retatrutide causing hair loss? A look at telogen effluvium during rapid weight loss, GLP-1 trial data, and what you can do about it.
Retatrutide for Sleep Apnea: The NEJM Trial Results
Retatrutide cut sleep apnea events by up to 34 an hour in two NEJM trials (October 2026). Results by dose, with and without diabetes, and versus tirzepatide.
Retatrutide and Weight Regain: What Happens When You Stop
Analysis of weight regain risk after stopping GLP-1 therapies and what retatrutide's TRIUMPH program tells us about long-term maintenance dosing.
Why You Can't Safely Buy Retatrutide Online: Gray Market Risks Explained
Online 'research peptide' retatrutide is unapproved and untested. What FDA testing and warning letters found, and why trial-grade product is different.
What Will Retatrutide Cost? Analyzing Eli Lilly's Pricing Signals
No price announced for retatrutide, but tirzepatide pricing, the biologic lawsuit, analyst projections, and Lilly's $3.5B plant offer clues on future cost.
Retatrutide in the UK and Europe: Regulatory Pathway and Expected Timeline
Retatrutide is not approved in the UK or EU. How the MHRA, EMA and NICE steps work, and our estimate of when it could reach patients (late 2028 UK, 2029 EU).
Retatrutide Dose Escalation Explained: Why Starting Low Matters
Why retatrutide doses are raised step by step, what the Phase 2 trial showed about starting at 2 mg instead of 4 mg, and how this helps with nausea.
Retatrutide and Dysesthesia: What the Phase 3 Data Actually Shows
Dysesthesia, an odd skin sensation, showed up in retatrutide's Phase 3 trials. How often it happened, how severe it was and why regulators will look at it.
Retatrutide and Liver Fat: The MASLD Data That Changed the Conversation
What retatrutide's Phase 2 liver-fat imaging showed, why glucagon matters for liver fat, and what the running SYNERGY trials will test in MASLD and MASH.
Does Retatrutide Preserve Muscle? What the Body Composition Data Shows
What retatrutide's body composition data show about fat lost versus lean mass lost, and what is still unknown about muscle and strength.
How Phase 3 Changed Retatrutide's Dosing Protocol — and Why It Matters
How retatrutide's dose escalation changed between Phase 2 and Phase 3, why Lilly made the change, and what it means for side effects.
The Future of Obesity Pharmacotherapy: From Single Agonists to Combination Approaches
Obesity drugs are moving from single GLP-1 agonists to dual and triple agonists and combinations. Where retatrutide sits among the drugs coming next.
Liver Fat Reduction With Retatrutide: Why the Phase 2 Data Are Significant
In Phase 2, retatrutide cut liver fat by about 82% at 24 weeks. What that means for fatty liver disease (MASLD) and why glucagon is the likely reason.
Putting 28.7% Weight Loss in Context: What Retatrutide's Numbers Mean
What 28% average weight loss looks like in practice, compared with bariatric surgery, diet programs and other drugs, and how many people reached each target.
Retatrutide FDA Approval Timeline: When Will It Be Available?
Lilly plans to file by Q1 2027, and the FDA says the application must be an NDA. Review takes 8 to 12 months, so here are the realistic approval dates.
Retatrutide vs. Mounjaro: Two Drugs, One Company, Different Targets
Lilly makes both tirzepatide (Mounjaro, Zepbound) and retatrutide. How dual and triple agonists differ, and where each drug fits for patients.
Retatrutide vs. Wegovy: What the Data Actually Shows
Retatrutide and semaglutide 2.4 mg (Wegovy) compared on weight loss, mechanism and side effects, and why comparing separate trials has limits.
Retatrutide Side Effects: What Clinical Studies Actually Show
Side effects reported in retatrutide trials: nausea and other stomach effects, how they change with dose, how many people stopped, and how that compares.
The TRIUMPH Phase 3 Program: Everything We Know
Lilly's TRIUMPH Phase 3 program for retatrutide: what each trial tested, which have reported (TRIUMPH-1 to 4) and which are still running.
Why the Glucagon Receptor Matters: The Third Component of Triple Agonism
Glucagon is what sets retatrutide apart from tirzepatide. How it may raise energy use and clear liver fat, and what the trials show so far.
What Phase 3 Means: Understanding the TRIUMPH Program
What a Phase 3 trial is, what the TRIUMPH and TRANSCEND trials were built to answer about retatrutide, and what comes after the results.
Why Triple Agonism Matters: The Next Frontier in Metabolic Medicine
Retatrutide acts on GLP-1, GIP and glucagon receptors at once. What each one does, and how this differs from semaglutide and tirzepatide.
Retatrutide in the Context of the GLP-1 Revolution
GLP-1 drugs changed obesity and diabetes care. How retatrutide, a triple agonist, builds on semaglutide and tirzepatide, and what it adds.
Breaking Down the Phase 2 Obesity Results: What the Numbers Actually Mean
The 2023 NEJM Phase 2 trial in plain English: up to 24.2% weight loss at 48 weeks on 12 mg, how many people hit each target, and what the endpoints mean.
How to Read Clinical Trial Data: A Practical Guide for Non-Scientists
A plain guide to trial results: endpoints, placebo-adjusted numbers, estimands, p-values and the traps to avoid, with examples from obesity drug trials.